A DLL3-targeted antibody-drug conjugate eradicates highgrade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 2015;7:302ra136.11. Johnson ML, Zvirbule Z, Laktionov K, et al. Rovalpituzumab Tesiri...
Galeazzi, M.; Bazzichi, L.; Sebastiani, G.D.; Neri, D.; Garcia, E.; Ravenni, N.; Giovannoni, L.; Wilton, J.; Bardelli, M.; Baldi, C.; et al. A phase IB clinical trial with Dekavil (F8-IL10), an immunoregulatory "armed antibody" for the treatment of rheumatoid arthritis,...
HSCs were cross-linked with 1% formaldehyde and immunoprecipitated with an anti-p65 antibody (Cell Signaling Technology, Danvers, MA, USA) or IgG as a negative control. Eluted DNA from the immunoprecipitation was analyzed by quantitative PCR using PCR primers that were designed to amplify the prom...
Specifically, siRNA-mediated knockdown of IL-11 sensitized the cells to paclitaxel-induced cell death, while anti-IL-11 antibody added to culture medium increased doxorubicin-induced apoptosis. Indeed higher IL-11 expression was associated with reduced progression-free and overall survival in a cohort...
10. Saunders LR, Bankovich AJ, Anderson WC, et al. A DLL3-targeted antibody-drug conjugate eradicates highgrade pulmonary neuroendocrine tumor-initiating cells in vivo. Sci Transl Med 2015;7:302ra136. 11. Johnson ML, Zvirbule Z, Laktionov K, et al. Rovalpituzumab Tesirine as a Maintena...
Anti-interleukin-12 p40 monoclonal antibody、Stellara、Sterrara + [13] 靶点 IL-12 x IL-23 作用方式 抑制剂 作用机制 IL-12抑制剂(白细胞介素-12复合体抑制剂)、IL-23抑制剂(白细胞介素-23复合体抑制剂) 治疗领域 免疫系统疾病感染消化系统疾病+ [4] ...
[5] McInnes IB, Mease PJ, Kirkham B, et al. (2015) Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lan...
Rademikibart (CBP-201) is a next-generation IL-4 receptor alpha-targeting antibody. OBJECTIVE: We sought to evaluate rademikibart in adults with moderate to severe atopic dermatitis. METHODS: A total of 226 patients were randomized, double-blind, to subcutaneous rademikibart (300 mg every 2 ...
NGM Biopharmaceuticals, Inc. recently announced a clinical trial collaboration and supply agreement with Merck to evaluate NGM707, NGM’s wholly owned novel ILT2/ILT4 dual antagonist antibody, in combination with...
Currently, IL-1β blockade with the human monoclonal antibody (mAb) canakinumab is being tested in a Phase II clinical trial for the treatment of low or intermediate risk MDS and CML (NTC04239157). Another interesting IL-1 blocking agent is the FDA-approved anakinra, the recombinant form of ...